Investing.com - Lantern Pharma reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Lantern Pharma announced earnings per share of $-0.21 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.54 on revenue of $0.00.
Lantern Pharma 's are up 100% and is trading at $4.47 , still down 57.18% from its 52 week high of $10.44 set on Monday, November 8, 2021.
Lantern Pharma follows other major Healthcare sector earnings this month
Lantern Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar